CoChat

Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models

Open access
Haendler · 2009 · International Journal of Oncology
Cited by 66

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

N-(2-aminophenyl)-4-[N-(pyridine-3yl-methoxy-carbonyl) aminomethyl] benzamide (MS-275) is a second generation histone deacetylase (HDAC) inhibitor with significant anti-tumor efficacy currently in clinical development. We investigated the effect of MS-275 treatment on various colon cancer cell lines, as well as on mouse xenograft models derived from human colorectal cancer. MS-275 exerted strong anti-proliferative effects in five cell lines and increased the acetylation of histones 3 and 4. In vivo testing of the compound in eight different models of human colon cancer derived from primary colorectal cancers or from established cell lines revealed that five models were responders, two non-responders and one an anti-responder. Gene expression profiles were determined in order to identify genes and pathways differentially regulated upon MS-275 treatment in responder versus non-responder models. Principle component analysis revealed a correlation of the anti-tumor efficacy with the sub-clustering of the MS-275 treatment groups in 7 out of 8 models. Although the overall gene expression pattern was rather unique for each individual model, 129 genes were significantly up- and 58 genes significantly down-regulated in at least 2 out of 5 responder models in response to MS-275 treatment. We identified potential biomarkers for response to MS-275, such as PRA1, MYADM and PALM2-AKAP2 which were up-regulated in all responder models and down-regulated or unchanged in all non-responder models. Our results provide a starting point for the development of clinically relevant biomarkers for predicting a response to MS-275 and the understanding of the mode of action of this HDAC inhibitor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijo_00000406

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

  • Combination therapy in combating cancer

    Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543

    “MS-275 selectively inhibits HDAC1/2 [111].”
  • Trials with ‘epigenetic’ drugs: An update

    Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237

    “…class I selective inhibitor, in- clude patients with a wide variety of hematologic and solid neoplasms (Knipstein and Gore, 2011) such as leukemia (Gojo et al., 2007; Lucas et al., 2004), melanoma (Gore et al., 2008), MDS (Fandy et al., 2009) and colorectal cancer (Bracker et al., 2009) (Table 5).”
    Background
  • HDAC11 is a novel drug target in carcinomas

    Deubzer, H. E., Schier, M. C., Oehme, I., Lodrini, M., Haendler, B., Sommer, A., & Witt, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.27876 · Cited by 112

    “For both, ‘‘broad spectrum’’-HDACi (vorinostat) and the newer class I HDACi (depsipeptide, MGCD0103 and MS-275/entinostat), the major toxicities reported include severe fatigue, gastrointestinal toxicity and hematological side effects, including reversible thrombocytopenia and neutropenia.(5,10) These observations are…”
  • Entinostat for treatment of solid tumors and hematologic malignancies

    Knipstein, J., & Gore, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.613822 · Cited by 110

    “No complete or partial responses were demonstrated; however, one heavily pretreated CRC patient with metastatic disease achieved 8 months of SD. Metastatic lesions in this patient had previously been rapidly progressive, but stabilized for a period of 4 months prior to slow progression over the subsequent months.”
    BackgroundInfluential

See all 66

Metadata

Authors
Haendler
Venue
International Journal of Oncology
Published
2009-09-01
Volume
35
Issue
4
Pages
909-20
ISSN
  • 1019-6439 (ISSN-L)
  • 1791-2423
OpenAlex
W2155759132
Cited by
66
References
11
FWCI
1.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.